TCGA-33-AAS8-01A-11R-A405-07
— · cohortSQ2
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortSQ2
- subtype
- cohortSQ2
- age_years
- 59
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V2+0.530
- MYC_TARGETS_V1+0.420
- DNA_REPAIR+0.400
- E2F_TARGETS+0.360
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.350
- UNFOLDED_PROTEIN_RESPONSE+0.340
- MTORC1_SIGNALING+0.320
- G2M_CHECKPOINT+0.300
- PANCREAS_BETA_CELLS+0.290
- OXIDATIVE_PHOSPHORYLATION+0.280
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.600
- INTERFERON_GAMMA_RESPONSE-0.550
- ALLOGRAFT_REJECTION-0.500
- INFLAMMATORY_RESPONSE-0.450
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.430
- IL6_JAK_STAT3_SIGNALING-0.420
- KRAS_SIGNALING_UP-0.390
- UV_RESPONSE_DN-0.360
- COMPLEMENT-0.350
- TGF_BETA_SIGNALING-0.330
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-LA-A446-01A-21R-A24Z-07 | — | cohortSQ2 | 0.913 |
| 2 | SRR2932827 | — | — | 0.906 |
| 3 | TCGA-CV-5432-01A-02R-1686-07 | — | — | 0.901 |
| 4 | TCGA-39-5037-01A-01R-1443-07 | — | cohortSQ2 | 0.900 |
| 5 | 5d2d4263-d17d-424f-9c82-bf665306d71f | — | — | 0.900 |
| 6 | TCGA-33-4532-01A-01R-1201-07 | — | cohortSQ2 | 0.894 |
| 7 | TCGA-85-8354-01A-31R-2326-07 | — | cohortSQ2 | 0.890 |
| 8 | TCGA-UF-A71A-06A-11R-A39I-07 | — | — | 0.889 |
| 9 | ERR2598250 | fetal | fetal | 0.884 |
| 10 | TCGA-NK-A5CR-01A-11R-A26W-07 | — | cohortSQ2 | 0.884 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 23 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V2 | 0.530 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.420 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.400 | Idelalisib | — uncovered |
| E2F_TARGETS | 0.360 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.350 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.340 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.320 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.300 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.290 | Cobimetinib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.280 | Remibrutinib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.280 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.230 | Remibrutinib | — uncovered |
| P53_PATHWAY | 0.130 | Idelalisib | — uncovered |
| GLYCOLYSIS | 0.100 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.100 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.090 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.090 | Idelalisib | — uncovered |
| APICAL_SURFACE | 0.080 | Temsirolimus | — uncovered |
| KRAS_SIGNALING_DN | 0.040 | Remibrutinib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.040 | Inavolisib | — uncovered |